Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Britain partners with Oxford firm to assess coronavirus vaccine T cell responses

10/22/2020 | 12:20am EST

LONDON (Reuters) - Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.

T cell immunity is thought to be essential to protection against infection from the SARS-COV-2 coronavirus, and could provide longer term immunity than antibodies.

The UK Vaccine Taskforce has chosen Oxford Immunotec to supply T cell testing for its assessment of different vaccine candidates.

"It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons," Kate Bingham, chair of the UK Vaccines Taskforce, said in a statement.

Britain has signed supply deals for six different coronavirus vaccine candidates, including those being made by AstraZeneca and Pfizer and BioNTech, seen as among the frontrunners in the race for a vaccine.

Oxford Immunotec said its techonology platform enabled the centralisation of fresh blood samples from different locations to measure the T cell response in a standardised way.

It said the platform, known as T-SPOT, was being used to identify the T cells made in response to the pathogen that causes tuberculosis.

(Reporting by Alistair Smout; editing by Barbara Lewis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
BIONTECH SE 4.79% 109.99 Delayed Quote.224.65%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
All news about ASTRAZENECA PLC
12:10pASTRAZENECA : India regulators probe alleged AstraZeneca shot reaction, trial co..
RE
07:42aUK secures two million more doses of Moderna's COVID-19 vaccine
RE
05:55aASTRAZENECA : UK confirms H5N8 bird flu on English turkey farm
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28UK regulator set to approve COVID-19 vaccine next week - FT
RE
11/28India's Modi visits key vaccine facilities as COVID-19 cases surge
RE
11/28UK appoints vaccines minister to oversee COVID inoculations
AQ
11/28India's Modi visits key vaccine facilities as COVID-19 case load surges
RE
11/28Oil prices post weekly gain ahead of OPEC+ meeting
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440